TB Alliance announces new research in partnership with Stop TB, TB REACH programs to find a newer and better drug for treating multi-drug resistant TB after TB Alliance was one of the approving partners for a new drug of multi-drug resistant TB announced in 2019.
TB Alliance commences partnership research to find another new innovative and better treatments of multi-drug resistant TB ahead of 2019 official use of new drug for multi-drug resistant TB.
TB Alliance stated that there is an open window of opportunity to treat the most deadliest and difficult to treat multi-drug resistant TB forms in the collaboration research through Stop TB Partnership’s TB REACH program and advise should be utilized well.
TB Alliance accepted to work with Stop TB Partnership’s TB REACH program in September 2019 to continue the work of eradicating TB especially the multidrug –resistant strain that remains difficult to eradicate even with the latest drugs. The research aims to find new drug of eradicating of the deadliest forms of drug –resistant TB that continues to account for millions of deaths every year around the world.
“These countries now have an opportunity to lead the way toward implementing new ways of treating highly drug-resistant forms of TB. We are greatly encouraged by this news and the hope it provides for patients in need,” stated president and CEO of TB Alliance Mel Spigelman.
TB Alliance listed the countries where multi-drug resistant TB failed treatment to be Belarus, South Africa, Tajikistan, Ukraine and other countries not mentioned.
“Extensively drug-resistant TB, which is especially difficult to treat, has been found in more than 127 countries,” stated TB Alliance.
This new research for multi-drug resistant TB came after FDA and Limited Population Pathway for Antibacterial and Antifungal Drugs approval of the historic new TB drug which was the second approval of a TB drug in 40 years and the first TB drug developed and registered by a nonprofit making organization in June 2019.
The June 2019 approved drug all -oral three drugs for treating multi-drug resistant tuberculosis was prescribed to be taken for six months and provided a shorter time of therapy and was considered more effective than the previous treatments of the multidrug-resistant TB which involved the use of many drugs upto eight antibiotics a day and daily injections for a period of 18 months or more.
“The associated novel regimen will hopefully provide a shorter, more easily manageable and highly efficacious treatment for those in need. Until very recently, people infected with highly drug-resistant TB had poor treatment options and a poor prognosis. The three-drug regimen consisting of bedaquilin, pretomanid and linezolid was studied in the pivotal Nix -TB trial across three cities in South Africa. Nix -TB data have demonstrated a successful outcome in patients after six months of treatment with BPaL and six -months posttreatment follow-up,” stated TB Alliance.
The TB Alliance work with Stop TB Partnership’s TB REACH program is ready to commence a new research before the official launch of the new drug for public use. The US,FDA and TB Alliance had submitted the new drug to European Medicines Agency for approval and WHO to include it in treatment guidelines for TB treatment and the US hopes to start using the drug by the end of 2019.
As the latest drug innovated to treat multi-drug resistant TB waits to commence official use before the end 2019, the new partnership will see work in innovation through their 37 projects on finding solutions on diagnostics and care efforts.